Funder
National Institute on Minority Health and Health Disparities
National Cancer Institute
Publisher
Springer Science and Business Media LLC
Reference48 articles.
1. Bross PF, Cohen MH, Williams GA, Pazdur R (2002) FDA drug approval summaries: fulvestrant. Oncologist 7:477–480
2. Howell A, Sapunar F (2011) Fulvestrant revisited: efficacy and safety of the 500-mg dose. Clin Breast Cancer 11:204–210
3. DeFriend DJ, Howell A, Nicholson RI, Anderson E, Dowsett M et al (1994) Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res 54:408–414
4. Jones SE, Pippen J (2005) Effectiveness and tolerability of fulvestrant in postmenopausal women with hormone receptor-positive breast cancer. Clin Breast Cancer 6(Suppl 1):S9–14
5. Robertson JF, Lindemann J, Garnett S, Anderson E, Nicholson RI et al (2014) A good drug made better: the fulvestrant dose-response story. Clin Breast Cancer 14:381–389
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献